Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9%As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47Fiscal 2026 constant currency organic revenue, EPS and free cash flow outlook increased DUBLIN, IRELAND , Nov. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 second quarter ended September 30, 2025. Total revenue from continuing opera ...

Core Points - STERIS plc announced a quarterly dividend of $0.63 per share, payable on December 18, 2025, to shareholders of record by November 18, 2025 [1] - The company is a leading global provider of products and services focused on infection prevention and enhancing patient care [2] Company Information - STERIS aims to create a healthier and safer world through innovative healthcare and life science products and services [2] - The company emphasizes its commitment to infection prevention as a core aspect of its operations [2] Contact Information - For investor relations, the contact person is Julie Winter, Vice President, who can be reached at Julie_Winter@steris.com or by phone at 440.392.7245 [3]

Group 1: Upslope Capital Management Performance - Upslope Capital Management reported a strong performance in Q3 2025, achieving a net return of +8.8%, outperforming the S&P Midcap 400 ETF (+5.5%) and HFRX Equity Hedge Index (+3.8%) [1] Group 2: STERIS plc Overview - STERIS plc, headquartered in Dublin, Ireland, specializes in infection prevention products and services, with a market capitalization of $23.73 billion as of October 22, 2025 [2] - The stock of STERIS plc experienced a one-month return of -1.44% but gained 5.91% over the last 52 weeks, closing at $242.37 per share [2] Group 3: STERIS plc Investment Insights - STERIS plc is recognized as a leader in infection prevention and sterilization, with approximately 75% of sales derived from service and consumables, historically achieving high single-digit organic growth [3] - The company's valuation is considered reasonable at 22x 2026 EPS, and it maintains a strong balance sheet with 1x net leverage, presenting opportunities for capital deployment [3] - Long-term growth drivers for STERIS plc include an aging global population and ongoing innovations in healthcare procedures and technology [3] Group 4: Hedge Fund Interest in STERIS plc - STERIS plc was held by 50 hedge fund portfolios at the end of Q2 2025, an increase from 46 in the previous quarter, indicating growing interest among institutional investors [4]

Core Insights - STERIS plc (STE) is set to announce its second-quarter fiscal 2026 results on November 6, with expectations of revenue and EPS growth [1][10] - The company reported adjusted EPS of $2.34 in the last quarter, exceeding the Zacks Consensus Estimate by 0.86% [1] - STE has consistently beaten earnings estimates in three of the last four quarters, with an average surprise of 2.02% [1] Revenue and EPS Estimates - The Zacks Consensus Estimate for revenues is $1.43 billion, reflecting a 7.4% increase year-over-year [2] - The EPS estimate stands at $2.38, indicating an 11.2% year-over-year growth [2] Segment Performance Expectations - Healthcare segment is expected to show robust growth, with a projected revenue increase of 5.9% year-over-year [5] - The Applied Sterilization Technologies (AST) segment is anticipated to see a 10.8% year-over-year revenue growth, driven by stable global MedTech customers and increased bioprocessing demand [6][7] - Life Sciences segment is projected to grow by 7.2% year-over-year, benefiting from strong consumables and services revenue [8] Earnings Surprise Potential - STERIS has an Earnings ESP of 0.00%, indicating a lower likelihood of beating earnings estimates this quarter [11] - The company currently holds a Zacks Rank of 4 (Sell), suggesting caution in investment decisions [11]

Core Insights - STERIS plc is a global leader in infection prevention and sterilization solutions with a market cap of $23.9 billion, providing a diverse range of products and services to healthcare sectors [1] Financial Performance - Analysts expect STERIS to report Q2 earnings of $2.38 per share, reflecting an 11.2% increase from $2.14 per share in the same quarter last year, with the company having consistently met or exceeded Wall Street's estimates in the past four quarters [2] - For fiscal 2026, earnings are projected to be $10.07 per share, a 9.2% increase from $9.22 in fiscal 2025 [3] Stock Performance - STERIS stock has increased by 7.9% over the past 52 weeks, underperforming the S&P 500 Index's 15.1% gain but outperforming the Health Care Select Sector SPDR Fund's 4.1% decline [4] Market Concerns - On September 25, STERIS shares fell by 3% following a national security investigation into medical equipment imports, which could result in new tariffs affecting various medical products, leading to concerns about supply chains and production costs across the healthcare manufacturing sector [5] Analyst Ratings - The consensus opinion on STERIS stock is a "Moderate Buy," with six out of nine analysts recommending a "Strong Buy" and three suggesting a "Hold," indicating a potential upside of 15% based on an average price target of $278.29 [6]

Core Points - STERIS plc will host a conference call to discuss its fiscal 2026 second quarter results on November 6, 2025, at 9:00 a.m. ET [1] - A press release detailing financial results will be issued after the U.S. market closes on November 5, 2025 [2] - A replay of the conference call will be available starting at 12:00 p.m. ET on November 6, 2025 [2] Company Overview - STERIS is a leading global provider of products and services that support patient care, focusing on infection prevention [3] - The company aims to help customers create a healthier and safer world through innovative healthcare and life science products and services [3]

Core Insights - STERIS plc's Healthcare segment is experiencing growth due to successful market adoption of its infection prevention products and capital equipment, with service revenues driving growth in the Applied Sterilization Technologies (AST) segment [2][4] - The company has shown sound financial health, but macroeconomic volatility and currency fluctuations pose concerns for its stock performance [2][10] Financial Performance - In the past year, STERIS shares increased by 4.8%, underperforming the industry growth of 17.8% and the S&P 500's rise of 18.4% [3] - The company has a market capitalization of $21.75 billion and an earnings yield of 4.20%, significantly higher than the industry's -5.82% [3] - For the first quarter of fiscal 2026, Healthcare reported an 8% year-over-year revenue growth, with consumable revenues up by 5% and capital equipment revenues up by 6% [4][8] Segment Analysis - The AST segment achieved a 13% year-over-year revenue growth, driven by a 12% increase in service revenues, with constant currency organic revenues in the low double digits [5][8] - The growth in the AST segment is attributed to bioprocessing demand and stable medical device volumes [5] Solvency and Debt - STERIS ended the first quarter of fiscal 2026 with $279.7 million in cash and cash equivalents, long-term debt of $1.90 billion, and a debt-to-capital ratio of 21.4%, down 2.2% year over year [9][8] Market Concerns - The macroeconomic environment is affecting STERIS' financial operations, with rising healthcare costs and procurement challenges impacting production costs [10][11] - Foreign currency exchange rate fluctuations pose a risk, as nearly 30% of the company's revenues are generated outside the U.S., influenced by geopolitical instability and supply chain disruptions [12] Future Outlook - The Zacks Consensus Estimate for STERIS' fiscal 2026 earnings per share indicates a 9.1% improvement at $10.06, with revenues expected to reach $5.91 billion, suggesting an 8.2% growth from fiscal 2024 [13]

Company Overview - STERIS plc is valued at a market cap of $24.4 billion and is a leading global provider of infection prevention, decontamination, and surgical products and services, primarily serving the healthcare, pharmaceutical, and research industries [1] - The company is headquartered in Dublin, Ireland, and has been operational since 1985, supporting hospitals, laboratories, and pharmaceutical companies with sterilization and surgical solutions [1] Market Position - STERIS is classified as a "large-cap" stock, with a strong base of recurring revenues from consumables, service contracts, and equipment maintenance, providing stability and resilience [2] - The company has a global presence in over 100 countries and maintains a durable competitive edge in highly regulated and growing healthcare markets [2] Stock Performance - STERIS shares recently reached a 52-week high of $253 on September 12, with a 2.8% increase over the past three months, outperforming the iShares U.S. Medical Devices (IHI), which saw a 1.2% dip [3] - Year-to-date, STE shares have gained 20.6%, significantly outpacing IHI's 3.4% increase, and have returned 18% over the past 52 weeks compared to IHI's marginal increase [4] Financial Performance - On August 6, STERIS reported strong Q1 FY2026 results, with revenue rising 9% to $1.39 billion and adjusted EPS improving 15% to $2.34, driven by strength across segments, particularly Applied Sterilization Technologies and Healthcare [5] - The company benefited from margin expansion, firm pricing, and operational efficiencies, leading management to raise its full-year revenue growth outlook to 8–9% from a previous 6–7% and increase its free cash flow forecast to $820 million [5] Competitive Landscape - In contrast, key rival AdaptHealth Corp. (AHCO) has underperformed, with its stock decreasing by 19.3% over the past 52 weeks and a decline of 3.2% year-to-date [6]

Group 1 - STERIS plc (NYSE: STE) reported Q1 FY'26 financial results in the first week of August, highlighting several high-quality takeaways [1] - The business has shown continued growth since the last publication in September 2023, indicating a stable operational performance [1] Group 2 - The company focuses on fundamental value drivers of business economics to identify high-probability long-term investment opportunities [1] - STERIS engages with a diverse range of partners across financial markets, including speculators, hedgers, and long-term traders [1]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks based on value, growth, and momentum characteristics, assigning ratings from A to F [3] - Value Score focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales [4] - Growth Score emphasizes a company's financial health and future growth potential based on earnings and cash flow [5] - Momentum Score identifies trends in stock prices and earnings estimates to optimize entry points for investments [6] - VGM Score combines the three Style Scores to highlight stocks with the best overall characteristics [6] Zacks Rank and Style Scores Interaction - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in stock selection [7] - Stocks rated 1 (Strong Buy) have historically outperformed the S&P 500, achieving an average annual return of +23.75% since 1988 [7] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [9] - The direction of earnings estimate revisions is crucial; stocks with lower ranks but high Style Scores may still face downward price pressure [10] Company Spotlight: Steris plc - Steris plc specializes in infection prevention and surgical support products, having rebranded after acquiring Synergy Health plc in 2015 [11] - Currently rated 3 (Hold) with a VGM Score of A, Steris is positioned as a potential growth investment [11] - The company forecasts a year-over-year earnings growth of 9.8% for the current fiscal year, supported by positive earnings estimate revisions [12] - Steris has an average earnings surprise of +2%, indicating strong performance relative to expectations [12]